


G-CSF – a wonderful molecule

Prof. Dr. med. Karl Welte




Medizinische Hochschule
Hannover




Donald Metcalf

The growth of mouse bone marrow
cells in vitro. Aust J Exp Bio Med Sci
1966



1964




Leo Sachs

The cloning of normal mast cells
in tissue cultures. J.Cell.Physiol.
1965

The early 1960s

Metcalf, D., Nature Review Cancer, 2010



Timeline | Major events in the development of the colony-stimulating factors



CSF, colony-stimulating factor; G-CSF, granulocyte-CSF; GM-CSF, granulocyte-macrophage-CSF; IL-3, interleukin 3; M-CSF, macrophage-CSF.

Purification of G-CSF

(40 L supernatant of the 5637 cell line: 5 µg G-CSF)



Proc. Natl. Acad. Sci. USA
Vol. 82, pp. 1526–1530, March 1985
Medical Sciences

Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor


(protein purification/hematopoietic stem cells)

KARL WELTE, ERICH PLATZER, LI LU, JANICE L. GABRILOVE, ESTER LEVI, ROLAND MERTELSMANN,
AND MALCOLM A. S. MOORE

Laboratory of Developmental Hematopoiesis, and Laboratory of Molecular Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Communicated by Lewis Thomas, October 24, 1984

MSKCC New York, G-CSF-Laboratory, 1984



Effects of G-CSF on Myelopoiesis






Table 2. Comparison of CFU-GEMM and BFU-E activities of pluripotent CSF (GM-CSF activity, 500 u/ml)

	CFU-GEMM			BFU-E		
	Exp. 1	Exp. 2	Exp. 3	Exp. 1	Exp. 2	Exp. 3
Medi-						
um*	0.3 ± 0.3	0	0	42 ± 6	17 ± 3	17 ± 2
LCM†	7 ± 1	3 ± 0	3.3 ± 0.3	67 ± 1	65 ± 3	34 ± 3
PP-						
CSF‡	7.7 ± 2.1	4 ± 0.8	2.3 ± 0.9	85 ± 6	31 ± 1	28 ± 2

Target cells were 5×10^4 per ml of low density, nonadherent, and T-cell-depleted normal human BM cells. Experiment 3 was done in the absence of hemin. The number of colonies is shown as the mean ± SEM.

*Iscove's modified Dulbecco medium plus 30% FCS.



Engraftment of G-CSFR (CD114)
positive cells in NSG-mice

AMINO ACID SEQUENCE REPORT

Sample Number: 062184ASample submitted by: K.W./L.S.**AMGen**Sample: Pluropactin

Laboratory: _____

Phone Ext.: _____

Sequence analyzed by: PL/RE/CGAmount of sample sequenced: 100 %Pmoles
nmolesμg
mgTotal cycles run 30Sequencing method: ABI 470 A / BeatricePretreatment at protein
laboratory: _____

Sequence identified: I-P-L-G-P-A-S-(S)-L-P-Q-X-M-
(M)-X-K-(R)-X-X-(R)-(L)-X-

¹
⁵
¹⁰
¹⁵
²⁰

Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells

LAWRENCE M. SOUZA, THOMAS C. BOONE, JANICE GABRILOVE, POR H. LAI,
KRISZTINA M. ZSEBO, DOUGLAS C. MURDOCK, VICKI R. CHAZIN, JOAN BRUSZEWSKI,
HSIENG LU, KENNETH K. CHEN, JEAN BARENDE, ERICH PLATZER,
MALCOLM A. S. MOORE, ROLAND MERTELSMANN, KARL WELTE





Fig. 3. Schematic of the constructions used to generate an *E. coli* expression vector for production of non-glycosylated phG-CSF.

-12 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1
ATG TGG TAC ATG ATC ATG TGG TGG ATG ATC ATG ATG ATG TGG TGG ATG ATC ATG ATG ATG TGG
10 9 8 7 6 5 4 3 2 1
GAT CCT GCA ATG ATC ATG TGG ATG ATC ATG ATG ATG TGG ATG ATC ATG ATG ATG TGG ATG
19 18 17 16 15 14 13 12 11 10
GAG GAA GTC ATG ATC ATG TGG ATG ATC ATG ATG ATG TGG ATG ATC ATG ATG ATG TGG ATG
28 27 26 25 24 23 22 21 20 19
ATG
37 36 35 34 33 32 31 30 29 28
ATG
46 45 44 43 42 41 40 39 38 37
ATG
55 54 53 52 51 50 49 48 47 46
ATG
64 63 62 61 60 59 58 57 56 55
ATG
73 72 71 70 69 68 67 66 65 64
ATG
82 81 80 79 78 77 76 75 74 73
ATG
91 90 89 88 87 86 85 84 83 82
ATG
100 99 98 97 96 95 94 93 92 91
ATG
109 108 107 106 105 104 103 102 101 100
ATG
119 118 117 116 115 114 113 112 111 110
ATG
129 128 127 126 125 124 123 122 121 120
ATG
139 138 137 136 135 134 133 132 131 130
ATG
149 148 147 146 145 144 143 142 141 140
ATG
159 158 157 156 155 154 153 152 151 150
ATG
169 168 167 166 165 164 163 162 161 160
ATG
179 178
ATG
189 188 187 186 185 184 183 182 181 180
ATG
199 198 197 196 195 194 193 192 191 190
ATG
209 208 207 206 205 204 203 202 201 200
ATG
219 218 217 216 215 214 213 212 211 210
ATG
229 228 227 226 225 224 223 222 221 220
ATG
239 238 237 236 235 234 233 232 231 230
ATG
249 248 247 246 245 244 243 242 241 240
ATG
259 258 257 256 255 254 253 252 251 250
ATG
269 268 267 266 265 264 263 262 261 260
ATG
279 278 277 276 275 274 273 272 271 270
ATG
289 288 287 286 285 284 283 282 281 280
ATG
299 298 297 296 295 294 293 292 291 290
ATG
309 308 307 306 305 304 303 302 301 300
ATG
319 318 317 316 315 314 313 312 311 310
ATG
329 328 327 326 325 324 323 322 321 320
ATG
339 338 337 336 335 334 333 332 331 330
ATG
349 348 347 346 345 344 343 342 341 340
ATG
359 358 357 356 355 354 353 352 351 350
ATG
369 368 367 366 365 364 363 362 361 360
ATG
379 378 377 376 375 374 373 372 371 370
ATG
389 388 387 386 385 384 383 382 381 380
ATG
399 398 397 396 395 394 393 392 391 390
ATG
409 408 407 406 405 404 403 402 401 400
ATG
419 418 417 416 415 414 413 412 411 410
ATG
429 428 427 426 425 424 423 422 421 420
ATG
439 438 437 436 435 434 433 432 431 430
ATG
449 448 447 446 445 444 443 442 441 440
ATG
459 458 457 456 455 454 453 452 451 450
ATG
469 468 467 466 465 464 463 462 461 460
ATG
479 478 477 476 475 474 473 472 471 470
ATG
489 488 487 486 485 484 483 482 481 480
ATG
499 498 497 496 495 494 493 492 491 490
ATG
509 508 507 506 505 504 503 502 501 500
ATG
519 518 517 516 515 514 513 512 511 510
ATG
529 528 527 526 525 524 523 522 521 520
ATG
539 538 537 536 535 534 533 532 531 530
ATG
549 548 547 546 545 544 543 542 541 540
ATG
559 558 557 556 555 554 553 552 551 550
ATG
569 568 567 566 565 564 563 562 561 560
ATG
579 578 577 576 575 574 573 572 571 570
ATG
589 588 587 586 585 584 583 582 581 580
ATG
599 598 597 596 595 594 593 592 591 590
ATG
609 608 607 606 605 604 603 602 601 600
ATG
619 618 617 616 615 614 613 612 611 610
ATG
629 628 627 626 625 624 623 622 621 620
ATG
639 638 637 636 635 634 633 632 631 630
ATG
649 648 647 646 645 644 643 642 641 640
ATG
659 658 657 656 655 654 653 652 651 650
ATG
669 668 667 666 665 664 663 662 661 660
ATG
679 678 677 676 675 674 673 672 671 670
ATG
689 688 687 686 685 684 683 682 681 680
ATG
699 698 697 696 695 694 693 692 691 690
ATG
709 708 707 706 705 704 703 702 701 700
ATG
719 718 717 716 715 714 713 712 711 710
ATG
729 728 727 726 725 724 723 722 721 720
ATG
739 738 737 736 735 734 733 732 731 730
ATG
749 748 747 746 745 744 743 742 741 740
ATG
759 758 757 756 755 754 753 752 751 750
ATG
769 768 767 766 765 764 763 762 761 760
ATG
779 778 777 776 775 774 773 772 771 770
ATG
789 788 787 786 785 784 783 782 781 780
ATG
799 798 797 796 795 794 793 792 791 790
ATG
809 808 807 806 805 804 803 802 801 800
ATG
819 818 817 816 815 814 813 812 811 810
ATG
829 828 827 826 825 824 823 822 821 820
ATG
839 838 837 836 835 834 833 832 831 830
ATG
849 848 847 846 845 844 843 842 841 840
ATG
859 858 857 856 855 854 853 852 851 850
ATG
869 868 867 866 865 864 863 862 861 860
ATG
879 878 877 876 875 874 873 872 871 870
ATG
889 888 887 886 885 884 883 882 881 880
ATG
899 898 897 896 895 894 893 892 891 890
ATG
909 908 907 906 905 904 903 902 901 900
ATG
919 918 917 916 915 914 913 912 911 910
ATG
929 928 927 926 925 924 923 922 921 920
ATG
939 938 937 936 935 934 933 932 931 930
ATG
949 948 947 946 945 944 943 942 941 940
ATG
959 958 957 956 955 954 953 952 951 950
ATG
969 968 967 966 965 964 963 962 961 960
ATG
979 978 977 976 975 974 973 972 971 970
ATG
989 988 987 986 985 984 983 982 981 980
ATG
999 998 997 996 995 994 993 992 991 990
ATG
1009 1008 1007 1006 1005 1004 1003 1002 1001 1000
ATG
1019 1018 1017 1016 1015 1014 1013 1012 1011 1010
ATG
1029 1028 1027 1026 1025 1024 1023 1022 1021 1020
ATG
1039 1038 1037 1036

Welte, K., et al., PNAS 1985
Souza, L., et al., Science 1986

Biochemical Characteristics of G-CSF:



174 amino acids
Glycosylation: yes
Molecular weight: 19.6 kD

Filgrastim (E.Coli):
175 amino acids
Glycosylation: no
MW18.7 kD,

Nagata, S., et al., Nature 1986,
G-CSF splice form : 177 amino acids

Poster in Wilsede 1984
Modern Trends in Human Leukemia VI
R Neth, RC Gallo, MF Greaves, et al.

Biological activities of a human pluripotent hemopoietic colony-stimulating factor.

Platzer E, Welte K, Lu L, Gabrilove JL, Yung YP, Nathan CF,
Mertelsmann R, Moore MA.

[Haematol Blood Transfus. 1985;29:418-22.](#)

United States Patent [19]

Welte et al.

[54] HUMAN PLURIPOTENT HEMATOPOIETIC COLONY STIMULATING FACTOR

[75] Inventors: **Karl Welte**, New York, N.Y.; Erich Platzer, Speldorf, Germany; **Janice L. Gabrilove**, New York, N.Y.; **Roland Mertelsmann**, Chappaqua, N.Y.; **Malcolm A. S. Moore**, Larchmont, N.Y.

[73] Assignee: **Sloan-Kettering Institute for Cancer Research**, New York, N.Y.

[21] Appl. No.: **280,582**

[22] Filed: **Jul. 26, 1994**

Related U.S. Application Data



[2]

United States Patent [19]

Souza

[54] HUMAN PLURIPOTENT GRANULOCYTE COLONY-STIMULATING FACTOR

[75] Inventor: **Lawrence M. Souza**, Thousand Oaks, Calif.

[73] Assignee: **Amgen Inc.**, Thousand Oaks, Calif.

[21] Appl. No.: **459,298**

[22] Filed: **Jun. 2, 1995**

Related U.S. Application Data




[11]

[45]

Das
Lusi
Cant
Miy
Nico
Metc
Dext
Abbe
Tsun
67-8
Okat
Metc
er-V
Clarl
Gabr
Nico
Welt
Sprir
nn



Nagata
Wang e
Welte e
398-40
Welte e
Zsebo e
Isuneska
Suggs e
(1981).
Nomura
Kawasa
Miura e
7th Ann




G-CSF in Primates




G-CSF in Primates



Welte, et al., J. Exp. Med. 165, 941, 1987







G-CSF in Primates



Welte, K., et al., J Exp Med 1987


EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROOPENIA AND ASSOCIATED MORBIDITY DUE TO CHEMOTHERAPY FOR TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM

JANICE L. GABRILOVE, M.D., ANN JAKUBOWSKI, M.D., PH.D., HOWARD SCHER, M.D.,
CORA STERNBERG, M.D., GEORGE WONG, PH.D., JOHN GROUS, M.D., ALAN YAGODA, M.D.,
KATHERINE FAIN, MALCOLM A.S. MOORE, PH.D., BAYARD CLARKSON, M.D., HERBERT F. OETTGEN, M.D.,
KIRBY ALTON, PH.D., KARL WELTE, M.D., AND LAWRENCE SOUZA, PH.D.



G-CSF in Childhood ALL (BFM2000):

Does administration of more chemotherapy in time lead to increased survival ?



Welte, K., et al. Blood 1996





Fig 2. Incidence and duration of febrile neutropenic episodes ($\text{ANC} < 0.5 \times 10^9/\text{L}$ and oral temperature $\geq 38.5^\circ\text{C}$) during the study period in the control group and r-metHuG-CSF group.

ALL-BFM 90 Survival (10 years)



A


1




2




3

B


1



2




3




4

Souza and Welte, Science 1986



Principle Underlying the Concurrent Use of Chemotherapy and Growth Factors That Stimulate Cell Division.


The concurrent use of growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) could enhance the cytotoxic effect of agents such as cytarabine on leukemia cells. Little is known about the effects of these growth factors on the subpopulation of putative leukemia stem cells, which may have a relatively low rate of proliferation, or the residual normal hematopoietic precursors.

**No. at Risk**

G-CSF	255	155	113	102	76	41
No G-CSF	265	129	100	87	52	33


Figure 2. Cumulative Rate of Overall Survival (Panel A) and Disease-free Survival (Panel B), According to the Assigned Treatment.


AML-BFM 98



* G-CSF 5-8 days or until ANC >500/mm³ except patients with > 5% Blasts on day 15

AML-BFM 98 Standard risk patients (without Down-S.): EFS (3 years)







G-CSFR isoform I

G-CSFR isoform IV


The isoform IV replaces the carboxy-terminal 87 aa
with 34 aa of **novel sequence**




normal ratio 200 : 1


Mobilization of hematopoietic stem cells by G-CSF

a




b





Paradigm shift of SCT by G-CSF mobilization
(Germany 1998 – 2008)

Choosing between GVHD and delayed engraftment




Kim Cates

Transplantation's balancing act !


Martin, PJ, Nature Medicine 2009

Morris, ES, Nature Medicine 2009




Severe congenital neutropenia

Genetic distribution in 122 patients with CN






Severe Chronic Neutropenia Registry, Europe

Long Term Course of Median Absolute Neutrophil Count in Patients with Severe Congenital Neutropenia






G-CSF induces Nampt and NAD⁺ in myeloid progenitors from CN patients






Skokowa, J., et al., Nat Med 2009; 15: 151- 8


Nampt induces G-CSF and G-CSFR in CD34 cells via Sirt1/C/EBPs



Nampt triggers myeloid differentiation of CD34⁺ cells




Vitamin B3 treatment increases number of neutrophilic granulocytes in healthy individuals




Skokowa, J., et al., Nat Med 2009; 15: 151- 8

Vitamin B3 treatment of patient with cyclic neutropenia




Treatment with G-CSF (3 ug/kg/d s.c.)



Treatment with Vitamin B3 (200 mg/kg/d p.o.)
without G-CSF

Hazard rates and cumulative incidence of MDS/AML and sepsis death in patients with SCN.

Cumulative incidence of MDS/AML (blue curve) and sepsis death (black curve) among patients who achieved an adequate mean absolute neutrophil count (ANC) by months 6–18 (≥ 2.188 cells $\times 10^9/l$) at doses of G-CSF less than or equal to 8 $\mu\text{g}/\text{kg}$ per d).





Corresponding cumulative incidence curves among patients who failed to achieve an adequate ANC despite higher doses of G-CSF.

Rosenberg, Zeidler, et al., BJH 2010

Zeidler EHA 2010

G-CSFR mutations in CN patients








Adopted from Germeshausen et al., Blood 2006

Leukemogenesis


Nampt deacetylates p53



Sirtuins at a Glance

Takashi Nakagawa and Leonard Guarente

Substrates and biological functions of SIRT1




Leukemogenesis

SIRT1 deacetylates p53 and FOXO3a  functional

inactivation of p53 and FOXO3a

SIRT1 also deacetylates β -catenin and by this may induce genomic instability

Model of the malignant transformation in CN



Donald Metcalf

Abstract |The four colony-stimulating factors (CSFs) are glycoproteins that regulate the generation and some functions of infection-protective granulocytes and macrophages. Recombinant granulocyte-CSF (G-CSF) and granulocyte-macrophage-CSF (GM-CSF) have now been used to increase dangerously low white blood cell levels in many millions of cancer patients following chemotherapy. These CSFs also release haematopoietic stem cells to the peripheral blood, and these cells have now largely replaced bone marrow as more effective populations for transplantation to cancer patients who have treatment-induced bone marrow damage.

Nature Review Cancer, 2010

Acknowlegement

G-CSF signaling



SCN Registry

Julia Skokowa
Basant Kumar Thakur
Lan Dan
Kshama Gupta

Cornelia Zeidler
European LLPs
SCNIR David Dale

Leukemias

Martin Schrappe
Haig Riehm
Dirk Reinhardt,
Ursula Creutzig

ELA2

Inga Köllner
Carmela Beger

Lentiviral vectors

Axel Schambach
Christopher Baum

G-CSF receptor mutations,

Manuela Germeshausen
Matthias Ballmaier

HAX 1

Christoph Klein
and his Lab



Bundesministerium
für Bildung
und Forschung



Deutsche José Carreras Leukämie-Stiftung e.V.



Elternverein
krebskranker Kinder
Hannover e.V.

